Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - oxycodone hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: citric acid monohydrate; sodium hydroxide; water for injections; sodium chloride; sodium citrate; hydrochloric acid - oxycodone wkt is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - oxycodone hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections; sodium citrate; sodium hydroxide; sodium chloride; hydrochloric acid; citric acid monohydrate - oxycodone wkt is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - oxycodone hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium citrate; water for injections; citric acid monohydrate; sodium hydroxide - oxycodone wockhardt is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - oxycodone hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; citric acid monohydrate; water for injections; sodium chloride; sodium hydroxide; sodium citrate - oxycodone wockhardt is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - alectinib hydrochloride, quantity: 161.33 mg (equivalent: alectinib, qty 150 mg) - capsule, hard - excipient ingredients: magnesium stearate; potassium chloride; carmellose calcium; maize starch; carnauba wax; hypromellose; hyprolose; titanium dioxide; lactose monohydrate; sodium lauryl sulfate; carrageenan; iron oxide red; iron oxide yellow; indigo carmine aluminium lake; shellac; glyceryl monooleate - alecensa is indicated for the treatment of patients with anaplastic lymphoma kinase (alk)-positive, locally advanced or metastatic non-small cell lung cancer (nsclc).

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - ephedrine hydrochloride, quantity: 30 mg - injection, solution - excipient ingredients: water for injections - ephedrine hydrochloride injection is indicated in the treatment of hypotension secondary to spinal anaesthesia.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ziprasidone hydrochloride, quantity: 87.2 mg - capsule, hard - excipient ingredients: sodium lauryl sulfate; sucrose; titanium dioxide; indigo carmine; ammonium chloride; sodium starch glycollate type b; lactose monohydrate; gelatin; macrogol 6000; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ziprasidone is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy. ziprasidone is indicated as monotherapy for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ziprasidone hydrochloride, quantity: 65.4 mg - capsule, hard - excipient ingredients: sodium starch glycollate type b; titanium dioxide; sucrose; macrogol 6000; indigo carmine; gelatin; sodium lauryl sulfate; ammonium chloride; purified water; lactose monohydrate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ziprasidone is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy. ziprasidone is indicated as monotherapy for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ziprasidone hydrochloride, quantity: 43.6 mg - capsule, hard - excipient ingredients: macrogol 6000; ammonium chloride; lactose monohydrate; purified water; titanium dioxide; sucrose; gelatin; sodium starch glycollate type b; sodium lauryl sulfate; indigo carmine; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ziprasidone is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy. ziprasidone is indicated as monotherapy for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ziprasidone hydrochloride, quantity: 21.8 mg - capsule, hard - excipient ingredients: gelatin; lactose monohydrate; sodium starch glycollate type b; purified water; sucrose; titanium dioxide; ammonium chloride; sodium lauryl sulfate; indigo carmine; macrogol 6000; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ziprasidone is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy. ziprasidone is indicated as monotherapy for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder.